Nakajima H, Takamori H, Hiyama Y, Tsukada W
Research Institute, Daiichi Pharmaceutical Co., Tokyo, Japan.
Clin Exp Immunol. 1990 Sep;81(3):441-5. doi: 10.1111/j.1365-2249.1990.tb05353.x.
We have investigated the effects of recombinant murine interferon-gamma (rIFN-gamma) on type II collagen-induced arthritis (CA) in DBA/l mice. Therapeutic as well as prophylactic treatment with subcutaneous rIFN-gamma, at 10(5) U/mouse six times a week, inhibited the development of CA without any obvious side effects. The accompanying suppression of anti-CII antibody responses may partly explain the inhibition of CA by rIFN-gamma. The possible role of the anti-inflammatory effect of systemic IFN-gamma in the inhibition of CA is discussed.
我们研究了重组鼠干扰素-γ(rIFN-γ)对DBA/l小鼠II型胶原诱导性关节炎(CA)的影响。每周六次皮下注射rIFN-γ,剂量为10⁵ U/小鼠,无论是治疗还是预防性治疗,均能抑制CA的发展,且无明显副作用。伴随的抗CII抗体反应的抑制可能部分解释了rIFN-γ对CA的抑制作用。本文讨论了全身IFN-γ的抗炎作用在抑制CA中可能发挥的作用。